Proteomics analysis of enzalutamide-treated castration-sensitive and castration-resistant prostate cancer cell lines

被引：0
|
作者：
Liburd, Lincoln E., II
Paromov, Victor
Pratap, Siddharth
Stewart, LaMonica
机构：
来源：
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION | 2024年 / 33卷 / 09期
关键词：
D O I：
10.1158/1538-7755.DISP24-C052
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
C052
引用
收藏
页数：3
相关论文
共 50 条
  • [41] Enzalutamide - a new agent for treatment of castration-resistant prostate cancer
    Wysocki, Piotr J.
    ONCOLOGY IN CLINICAL PRACTICE, 2013, 9 (05): : 186 - 190
  • [42] Treatment of metastatic castration-resistant prostate cancer (mCRPC) with enzalutamide
    Baciarello, Giulia
    Sternberg, Cora N.
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2016, 106 : 14 - 24
  • [43] Metformin in overcoming enzalutamide resistance in castration-resistant prostate cancer
    Simpson, Kendall
    Allison, Derek B.
    He, Daheng
    Liu, Jinpeng
    Wang, Chi
    Liu, Xiaoqi
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2025, 392 (01):
  • [44] Enzalutamide in castration resistant prostate cancer
    Rios Gonzalez, Emilio
    Martinez-Pineiro, Luis
    ARCHIVOS ESPANOLES DE UROLOGIA, 2018, 71 (08): : 664 - 675
  • [45] Healthcare Costs for Metastatic Castration-Resistant Prostate Cancer Patients Treated with Abiraterone or Enzalutamide
    Rana, Dikshyanta
    Geue, Claudia
    Baillie, Kelly
    Pan, Jiafeng
    Mueller, Tanja
    Laskey, Jennifer
    Bennie, Marion
    Clarke, Julie
    Jones, Robert J.
    Brown, Ailsa
    Wu, Olivia
    PHARMACOECONOMICS-OPEN, 2022, 6 (02) : 303 - 313
  • [46] Healthcare Costs for Metastatic Castration-Resistant Prostate Cancer Patients Treated with Abiraterone or Enzalutamide
    Dikshyanta Rana
    Claudia Geue
    Kelly Baillie
    Jiafeng Pan
    Tanja Mueller
    Jennifer Laskey
    Marion Bennie
    Julie Clarke
    Robert J. Jones
    Ailsa Brown
    Olivia Wu
    PharmacoEconomics - Open, 2022, 6 : 303 - 313
  • [47] Serum γ-Glutamyltransferase as a Prognostic Biomarker in Metastatic Castration-resistant Prostate Cancer Treated With Enzalutamide
    Takemura, Kosuke
    Ito, Masaya
    Nakanishi, Yasukazu
    Kataoka, Madoka
    Sakamoto, Kazumasa
    Suzuki, Hiroaki
    Tobisu, Ken-ichi
    Koga, Fumitaka
    ANTICANCER RESEARCH, 2019, 39 (10) : 5773 - 5780
  • [48] Natural killer cell activity in patients with metastatic castration-resistant prostate cancer treated with enzalutamide.
    Zedan, Ahmed
    Nederby, Line
    Volmer, Lone
    Madsen, Christine Vestergaard
    Sorensen, Bente E.
    Hansen, Torben
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
  • [49] Transcriptomic Profiling Analysis of Castration-Resistant Prostate Cancer Cell Lines Treated with Chronic Intermittent Hypoxia
    Lee, Chung Lyul
    Lee, Minji
    Lee, Ji Yong
    Hong, Sin-Hyoung
    Yang, Seung Woo
    Min, Ji-Hyeon
    Lee, Dong-Eon
    Baek, Joonyoung
    Kim, Chanseul
    Lim, Jae Sung
    Song, Ki Hak
    Shin, Ju Hyun
    Kim, Gun-Hwa
    CANCERS, 2022, 14 (16)
  • [50] Proteome profiling of enzalutamide-resistant cell lines and serum analysis identified ALCAM as marker of resistance in castration-resistant prostate cancer
    Csizmarik, Anita
    Keresztes, David
    Nagy, Nikolett
    Bracht, Thilo
    Sitek, Barbara
    Witzke, Kathrin
    Puhr, Martin
    Tornyi, Ilona
    Lazar, Jozsef
    Takacs, Laszlo
    Kramer, Gero
    Sevcenco, Sabina
    Maj-Hes, Agnieszka
    Juranyi, Zsolt
    Hadaschik, Boris
    Nyirady, Peter
    Szarvas, Tibor
    INTERNATIONAL JOURNAL OF CANCER, 2022, 151 (08) : 1405 - 1419
12345